Medicare Now Covers Weight-Loss GLP-1 Drugs at $50 a Month

Medicare has never covered a drug prescribed only for obesity - until July 1, 2026. That day, the Centers for Medicare and Medicaid Services launched a demonstration called the Medicare GLP-1 Bridge, making Wegovy, Foundayo, and Zepbound available to eligible Part D enrollees for $50 a month. The program runs through December 31, 2027. At list price, these medications typically run $900 or more a month.

The Bridge runs outside the standard Part D benefit. Part D plans carry no financial risk for it - Medicare pays manufacturers directly for most of the cost. CMS set it up that way to avoid waiting for full plan-year enrollment changes.

Which drugs are covered

The Bridge covers Wegovy (all formulations, including the oral tablet), Foundayo (all formulations), and Zepbound in its KwikPen form only.

Ozempic, Rybelsus, and Mounjaro are not part of the Bridge. Those drugs share GLP-1 chemistry but are used under Medicare for type 2 diabetes or cardiovascular risk reduction - conditions already covered under regular Part D. If your doctor prescribes Ozempic for diabetes, nothing changes: you fill it through your standard Part D plan at your usual cost-sharing rate.

Who qualifies

Eligibility turns on body mass index and clinical conditions, broken into three tiers.

Two additional rules tighten the pool. You must be enrolled in a Medicare Part D plan - a standalone plan or a Medicare Advantage plan with drug coverage. And you cannot have a condition for which GLP-1 drugs are already covered under Part D - type 2 diabetes, obstructive sleep apnea, or metabolic liver disease. If you filled a GLP-1 prescription through your Part D plan at any point in 2026, you are also excluded. KFF estimates that after all filters, about 3.8 million Part D enrollees qualify.

How the $50 copay works

The $50 monthly copay is your full out-of-pocket cost for the Bridge medication - no deductible, no coinsurance. It does not, however, behave like a regular Part D copay.

The $50 sits on top of whatever you spend through regular Part D and does not help you reach the $2,100 cap faster. For beneficiaries who also get Extra Help - the subsidy that reduces drug costs for people with limited income - the $50 is not reduced. Everyone eligible pays the same amount regardless of income.

How to get a prescription

Your prescriber submits a prior authorization request before you can fill a Bridge medication. CMS targets a 72-hour turnaround. Once the authorization is in place, refills do not need a new one unless you switch drugs. The request goes through a CMS-run process, not your Part D plan.

After approval, you fill the prescription at any in-network pharmacy. The pharmacist runs it through the Bridge system, not your regular Part D benefit. Have your Medicare card ready.

What happens after 2027

The Bridge was planned as a six-month program. In April 2026, CMS extended it through December 31, 2027, citing insufficient plan participation in the BALANCE model - the longer-term demonstration CMS had intended to follow this one. Nothing is settled past 2027. CMS has said guidance is coming, but no coverage pathway has been set.

During open enrollment, October 15 to December 7, 2026, check whether plans in your area will participate in any 2027 GLP-1 coverage. Plan choice this fall could affect your access next year.

Where things stand

Medicare has covered GLP-1 drugs for diabetes for years. This is the first time it covers them for obesity alone. The $50 copay and the required prior authorization add real steps, and nothing is guaranteed past 2027. If you have the qualifying BMI and conditions, talk to your doctor now - the program runs 18 months total, and several of those are already gone. For a clinical look at GLP-1 therapy for older adults, see our guide to GLP-1 drugs and seniors. If money is tight, check whether you qualify for Medicare Savings Programs and Extra Help, which cover the Part B premium and reduce standard Part D costs, though they do not extend to the Bridge $50.

This article is a news report for general information and is not medical or financial advice. Eligibility criteria described above are based on CMS guidance current as of July 2026 and may change. Confirm your individual eligibility with your prescriber and your Medicare plan.